|
|
HIRONIC has received approval from Bahrain’s National Health Regulatory Authority (NHRA) for two of its devices, NEW DOUBLO 2.0™ and DOUBLO-GOLD™. Both devices are now officially approved for medical aesthetic use in Bahrain, expanding HIRONIC’s presence in the Middle East. NEW DOUBLO 2.0™ combines HIFU, RF, and RF microneedling in a single triple platform based on HIRONIC’s MFU & RF Synergy technology. Its multi-layer approach is designed to support skin lifting, tightening, and rejuvenation treatments, from the superficial layers to the SMAS.
DOUBLO-GOLD™ is a HIFU device from HIRONIC’s DOUBLO line, designed to support non-invasive skin lifting and tightening treatments.
HIRONIC said the approvals reflect its continued commitment to bringing reliable, innovative, and clinically relevant technologies to aesthetic practices around the world.
Device classifications and approved uses may vary by country. Please refer to local regulatory authorities for country-specific approval details.
2026-11-20
|
|
|
HIRONIC has received medical device approval from Malaysia’s Medical Device Authority (MDA) for NEW DOUBLO 2.0™. The approval marks another important milestone for HIRONIC’s MFU & RF Synergy technology.
A TRIPLE PLATFORM FOR MULTI-LAYER TREATMENT
NEW DOUBLO 2.0™ combines HIFU, RF, and RF microneedling in a single triple platform. Its multi-layer approach is designed to support skin lifting, tightening, and rejuvenation treatments, from the superficial layers to the SMAS. With multiple cartridges and handpieces, the device allows medical aesthetic professionals to work with precision, flexibility, and efficiency.
HIRONIC said the approval reflects its continued commitment to bringing reliable, innovative, and clinically relevant technologies to aesthetic practices around the world.
Device classifications and approved uses may vary by country. Please refer to local regulatory authorities for country-specific approval details.
2026-11-17
|
|
|
HIRONIC, a medical aesthetic device company, participated in the ASLS KOREA 2026 Autumn International Conference, held at COEX in Seoul on November 7–8. At the conference, the company exhibited its key products and hosted academic lectures. HIRONIC’s booth featured two of its latest devices. MIGLOU™ is a microwave energy-based device that delivers focused 2.45GHz microwave energy to the target area for skin tightening and contouring. SYNERJET PRO™ is a needle-free drug delivery device that combines microjet, electroporation, and plasma technologies in a single system.
In October 2026, HIRONIC held its first online Global Launch Symposium for overseas distribution partners, where it introduced MIGLOU™ and SYNERJET PRO™ as its new products.
HIRONIC said it will continue to communicate with medical professionals through academic events and a variety of on-site programs, aiming to deepen understanding of its products and enhance their clinical value.
2026-11-12
|
|
|
Hironic Hosts First Online Global Launch Symposium for Overseas Distributors, Unveiling 'MIGLOU' and 'SYNERJET PRO'SEOUL — Hironic, a medical aesthetic device specialist, announced on the 21st that it successfully held its first online global launch symposium for overseas distribution partners on the 14th and 15th. During the event, the company introduced its latest innovations: MIGLOU and SYNERJET PRO. Organized in celebration of Hironic's 20th anniversary, the symposium was hosted by the company's global clinical training platform, "H-Academy." The sessions were divided across three major regions—Europe, the Middle East, and Africa (EMEA); Asia-Pacific (APAC); and the Americas—and broadcast live from Seoul to accommodate local time zones. Around 120 representatives from distribution partners across 31 countries attended the event. SYNERJET PRO is a needle-free injector combining three distinct technologies: microjet delivery, low-frequency stimulation via electroporation tips, and plasma. In April and August of this year, the device received 510(k) clearances from the U.S. Food and Drug Administration (FDA) for its electrosurgical plasma function and transdermal electrical stimulation for aesthetic purposes, respectively. MIGLOU utilizes 2.45 GHz microwave energy alongside Hironic's proprietary Focused Intensive Microwave (FIM) technology. The device also features contact cooling capabilities and two smart safety sensors to ensure safe and precise delivery. Hironic plans to leverage the symposium to deepen collaboration with its global distribution network and expand regional supply in line with local regulatory approval timelines worldwide. "Through this symposium, we shared real-world clinical treatment insights for both MIGLOU and SYNERJET PRO with our partners around the globe," said Jin-woo Lee, CEO of Hironic. "We will translate the strong interest from partners across these three regions into new business opportunities and accelerate our global market expansion."
2026-11-02
|
|
|
HIRONIC has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for SYNERJET PRO's technologies, and has completed all related device and facility registrations. The clearances cover SYNERJET PRO's core electrosurgical and microcurrent stimulator functions. Its microjet technology has been formally listed. The milestone marks HIRONIC's expansion into the United States, the world's largest aesthetic medical device market. A NEEDLE-FREE APPROACH TO SKIN TREATMENT
Already cleared by Korea's Ministry of Food and Drug Safety (MFDS), SYNERJET PRO combines HIRONIC's proprietary Cold Plasma and Electroporation technologies with a high-precision microjetting system. Where traditional needle-based treatments can involve pain, downtime, and results that vary with practitioner skill, SYNERJET PRO delivers cold plasma energy and microcurrent stimulation directly to the skin's surface through a dedicated plasma handpiece and a distance-controlled electroporation tip. The microjet then delivers active solutions through the skin with greater consistency and less impact on surrounding tissue.
BUILT FOR THE GROWING SKIN BOOSTER MARKET
As the skin booster category expands rapidly alongside Botox and fillers, SYNERJET PRO has gained traction among practitioners and patients seeking effective results with minimal pain and downtime. The device combines three energy modalities in a single treatment, adapts to a wide range of skin conditions, and maintains stable performance over extended use — all contributing to significantly improved absorption of active ingredients. Treatment times are short and require no separate anesthesia, with customized application available across areas such as the face and scalp.
A RIGOROUS CLEARANCE, AND A PLATFORM FOR GLOBAL GROWTH
FDA 510(k) clearance reflects one of the most demanding regulatory reviews in the medical device industry, confirming that SYNERJET PRO's electrosurgical and microcurrent stimulator functions meet strict U.S. safety and performance standards. Supported by HIRONIC's own clinical and technical data, the clearance strengthens confidence among medical institutions and distribution partners worldwide.
With the U.S. market — valued at roughly KRW 12 trillion annually — now in reach, HIRONIC will begin full-scale supply of SYNERJET PRO through local distribution partners. The company plans to use this clearance as a foundation for accelerating regulatory approvals and distribution expansion across Europe, the Middle East, and Asia.
"FDA clearance for SYNERJET PRO reflects the strength of HIRONIC's technology being recognized on the global stage," said CEO Jinwoo Lee. "Starting with the U.S., we will continue delivering differentiated solutions in the global aesthetic device market and driving sustained revenue growth."Device classifications and approved uses may vary by country. Please refer to local regulatory authorities for country-specific approval details.
2026-09-10
|
|
|
HIRONIC marked the 20th anniversary of its founding on July 12, 2026. The company was established in 2006 as SP Medical, a name derived from "Success Partner," and has since grown into a KOSDAQ-listed developer and manufacturer of medical aesthetic devices with a presence in more than 60 countries.
Two Decades of Development
HIRONIC's founding period (2006–2010) centered on the development of its first medical devices and the establishment of its early patent portfolio. Between 2011 and 2016, the company listed on KOSDAQ and introduced the DOUBLO line of devices, a technology platform later upheld through a defended patent ruling.
From 2017 to 2020, HIRONIC received FDA and CE approvals for multiple device lines, expanding its distribution beyond the Korean market. The period from 2021 to 2023 saw continued growth in international distribution and industry recognition. Most recently, the company has launched SYNERJET PRO™ and MIGLOU™, both of which have received Korea MFDS approvals in 2026.
Current Operations
HIRONIC's product portfolio today includes SYNERJET PRO™, MIGLOU™, New Doublo™ (marketed in Korea as V-RO LIFTING™), and PICOHI™, covering applications in skin treatment, body contouring, and related aesthetic procedures. The company continues to work with distributors and physicians across its international markets.
In a statement marking the anniversary, HIRONIC said the milestone reflects two decades of work with its distributors, partner physicians, and patients, and that the company intends to continue developing new devices and expanding its international regulatory approvals in the years ahead.
2026-07-13
|
|
|
HIRONIC, a global medical aesthetic device company marking its 20th anniversary in 2026, announced today that its MIGLOU™ device has received medical device approval from Korea's Ministry of Food and Drug Safety (MFDS). The approval adds MIGLOU™ to HIRONIC's growing portfolio of MFDS-certified technologies, reinforcing the company's continued investment in clinically validated, next-generation aesthetic solutions for medical professionals worldwide.
A New Approach to Skin Tightening and ContouringMIGLOU™ is built on HIRONIC's proprietary 2.45GHz Focused Intensive Microwave (FIM) technology, engineered to deliver targeted energy for skin tightening and contouring treatments. The platform reflects HIRONIC's ongoing commitment to developing differentiated technologies that address evolving needs in the medical aesthetics field. The approval marks another step in HIRONIC's 20th anniversary year, reflecting the company's continued focus on research-driven development and a regulation-first approach to bringing new technologies to the global aesthetic market.Strengthening HIRONIC's Global Technology PortfolioThe MFDS approval positions MIGLOU™ alongside HIRONIC's established device lines — including New Doublo™, SYNERJET PRO™, and PICOHI™ — as part of a comprehensive technology platform serving medical aesthetic partners in more than 60 countries. With MFDS, FDA, and CE certifications across its portfolio, HIRONIC continues to expand its footprint through a rigorous, regulation-first approach to product development.About HIRONICFounded in 2006, HIRONIC is a KOSDAQ-listed medical aesthetic device company celebrating its 20th anniversary in 2026. HIRONIC develops and manufactures energy-based aesthetic devices distributed across more than 60 countries, with a portfolio spanning HIFU, RF, laser, and needle-free delivery technologies.
2026-07-09
|
|
|
HIRONIC took part in IMCAS Asia 2026 (19th Edition), one of Asia's most
prestigious aesthetic medicine conferences, held June 19–21 at The Athenee
Hotel, Bangkok. In cooperation with Thai partner, HIRONIC presented its latest innovations in energy-based
aesthetic devices to a global audience of practitioners and industry experts. A Showcase of HIRONIC's Core TechnologiesAt the booth, HIRONIC introduced three key
devices spanning the company's core treatment categories: PICOHI™, HIRONIC's
picosecond laser platform for pigmentation and skin revitalization; SYNERJET
PRO™, the brand's needle-free triple-action delivery platform combining
microjetting, electroporation, and cold plasma; and the flagship New Doublo™,
HIRONIC's advanced MFU+RF platform for lifting and skin tightening. Together,
the lineup gave attendees a comprehensive look at how HIRONIC's technologies
address needs across skin pigmentation, scar remodeling, and skin tightening. Expert Lecture Spotlights MIGLOU™'s
Proprietary FIM TechnologyA highlight of the conference was the
Expert Lecture delivered by Dr. Thitikom Limrattanamekha, held during the Laser & EBD Session at The Athenee Hotel. In his presentation, "MIGLOU™
2.45 GHz: Precision UHF Technology for Non-Invasive Fat Lipolysis and
Contouring," Dr. Thitikom outlined the clinical advantages of MIGLOU™'s
focused intensive microwave (FIM) technology — a modality proprietary to
HIRONIC and the first of its kind in the world. His lecture detailed how
MIGLOU™'s precision UHF approach enables non-invasive fat lipolysis and body
contouring with a distinct mechanism of action compared to existing
energy-based technologies, drawing strong engagement from attending
practitioners. Strengthening HIRONIC's Presence in
Southeast AsiaIMCAS Asia 2026 offered HIRONIC an
important opportunity to deepen its relationship with practitioners across
Southeast Asia. As HIRONIC celebrates its 20th anniversary in 2026, events like IMCAS
Asia continue to play a key role in the company's global expansion strategy,
connecting its technologies with the clinicians and markets shaping the future
of aesthetic medicine. HIRONIC thanks Dr. Thitikom Limrattanamekha
for his insightful lecture, its Thai partner for their continued collaboration,
and all attendees who visited our booth during the conference.
For more information about PICOHI™,
SYNERJET PRO™, New Doublo™, or MIGLOU™, please visit our website or contact
your regional HIRONIC representative.
2026-07-06
|
|
|
Last Saturday, HIRONIC welcomed an elite audience of leading aesthetic experts and top users from Korea and Japan for a private launching preview — an intimate, high-level event dedicated to unveiling two groundbreaking new devices set to redefine the non-invasive aesthetics landscape. Two Landmark Innovations UnveiledThe event introduced two next-generation devices: an advanced contouring and face lifting platform powered by microwave technology, available for export as MIGLOU™, and a revolutionary needle-free injector that uniquely combines three technologies — micro-jetting, electroporation, and plasma — in a single platform, available for export as SYNERJET PRO™.Four Immersive Expert LecturesThe launch was enriched by four in-depth lectures delivered by four of Korea's foremost aesthetic experts, offering clinical insights, hands-on perspectives, and forward-looking analysis on both devices and the broader direction of non-invasive aesthetics.Expert Insights on HIRONICAcross the presentations, experts consistently highlighted what sets HIRONIC apart in a crowded market. HIRONIC devices are recognized for their exceptional build quality, and the brand has remained steadfastly focused on non-invasive technologies — always prioritizing reduced patient discomfort alongside improved clinical efficacy. It is this unwavering philosophy, experts noted, that allows HIRONIC devices to consistently outperform competitors.A New Standard in Microwave-Based ContouringOn the microwave contouring device, experts drew particular attention to its proprietary FIM (Focused Intensive Microwave) technology — a uniquely advanced feature that enhances treatment efficiency while delivering the same energy output. This innovation, experts emphasized, is an entirely distinctive advancement that elevates MIGLOU™ (export name) to true second-generation microwave technology status, setting it apart from all currently available solutions and creating clear, immediate market value.Redefining Needle-Free DeliveryRegarding the triple-technology needle-free injector, experts were equally emphatic: combining micro-jetting, electroporation, and plasma into a single device is not incremental progress — it is a meaningful leap forward. When these three technologies work in synergy, they significantly enhance active ingredient absorption, a benefit now supported by recent clinical studies. Experts underscored that SYNERJET PRO™ (export name) directly overcomes the limitations of currently available needle-free solutions, positioning it as an undeniable step toward shifting the aesthetics industry from the injection era into a new age of advanced needle-free delivery.Setting the Course for the Future of Non-Invasive AestheticsThe private launch preview was more than a product reveal — it was a statement of direction. With two devices that each advance their respective categories in meaningful, clinically relevant ways, HIRONIC once again demonstrated its commitment to pushing the boundaries of non-invasive aesthetics. As both platforms make their way to markets worldwide, the industry will be watching closely — and if the response from Korea and Japan's top experts is any indication, the impact is set to be significant.
2026-06-04
|
|
|
HIRONIC announced on May 15 that it has signed an exclusive supply agreement with EMAGE Medical, a U.S.-based medical device distribution company, for its “next-generation RF combination platform” in the United States.The agreement will be carried out under an OEM model and will remain valid for two years from May 2026. The contract is also structured to allow an extension through mutual agreement between the two companies.EMAGE Medical is a medical device distribution company headquartered in Charlotte, North Carolina, and has established specialized medical aesthetic sales channels in the United States. During the contract period, EMAGE Medical plans to supply HIRONIC’s platform device under a locally customized brand, based on its exclusive sales and distribution rights across the U.S. market.The agreement includes a minimum annual purchase quantity clause. According to the company, this provision is intended to ensure active sales activities by the partner company. At the same time, the agreement includes conditions allowing the minimum purchase obligation to be adjusted in consideration of regulatory changes, including the FDA approval timeline, thereby balancing risk management for both parties.Based on technical and regulatory cooperation with EMAGE Medical, HIRONIC will support the local brand launch in the United States. The company also plans to build clinical case data and establish a network of key opinion leaders, or KOLs.The “next-generation RF combination platform” is characterized by the integration of RF, or radiofrequency, and Cold Plasma technologies into a single device. With five types of handpieces, including RF microneedling, Cold Plasma, and Circle monopolar RF, the platform supports a wide range of clinical applications, including skin lifting, tightening, scar and wrinkle improvement, and women’s health.In particular, the company explained that the sequential combination protocol using RF microneedling and Cold Plasma is designed to enhance collagen activation while minimizing post-procedure inflammation.A HIRONIC official stated, “This exclusive supply agreement in the United States, the world’s largest medical aesthetic market, demonstrates that our technology has been recognized in the global market.” The official added, “We will continue to strengthen our competitiveness in the medical aesthetic market by enhancing our technological capabilities and expanding strategic partnerships.” Reporter: Seong-hye Kim, hankyung.com[shkimmy@hankyung.com]Translation of the original articleOriginal article link: https://www.hankyung.com/article/202605158616O
2026-05-18
|
|
|
HIRONIC won the grand prize in the medical aesthetic device category for the ninth consecutive year at Money Today’s “2026 Service Customer Satisfaction Awards Chosen by Consumers,” held on April 29 at the Press Center in Jung-gu, Seoul.The Service Customer Satisfaction Awards Chosen by Consumers are presented to outstanding companies that achieve customer satisfaction by providing high-quality services across various industries.HIRONIC is a company specializing in medical aesthetic devices that implement technologies such as HIFU, or high-intensity focused ultrasound, RF, or radiofrequency laser, and Micro-Jetting. Its flagship product is V-RO ADVANCE, exported as New Doublo 2.0™, which was the world’s first device to enable three procedures—HIFU, RF, and Micro Needle—in a single platform.HIRONIC is introducing its needle-free energy devices, SYNERJET and SYNERJET PRO™, to both the domestic and global markets. SYNERJET gently refines the skin surface through uniform jetting technology, precise pressure control, and plasma technology. It also reduces user fatigue during extended use through its lightweight handpiece and intuitive operating system.SYNERJET PRO™ is a medical device that combines Micro-jetting, Electroporation, and Plasma technologies. It is designed to enable more precise and uniform procedures. Reporter: Nami HeoTranslation of the original articleOriginal article link: https://www.mt.co.kr/industry/2026/04/29/2026042814203330182
2026-05-18
|
|
|
HIRONIC announced that its non-invasive skin improvement medical device, SYNERJET PRO®, has officially obtained domestic medical device approval after successfully passing the Medical Device Technical Document Review (SR) by the Ministry of Food and Drug Safety (MFDS) and completing the certification application process through the National Institute of Medical Device Safety Information.This approval officially recognizes that HIRONIC’s independently developed needle-free microjet technology complies with domestic medical device standards and specifications. It is expected to serve as an opportunity to strengthen both HIRONIC’s competitiveness in the domestic market and its credibility in the global market.SYNERJET PRO® is a non-invasive drug and cosmetic solution delivery medical device based on Needle-free Microjetting technology independently developed by HIRONIC. It delivers active ingredients evenly into the skin layers using pressure alone, without needles, making it applicable to a wide range of dermatology and plastic surgery procedures, including treatments for patients with needle phobia. By expanding its lineup from the existing SYNERJET to the upgraded SYNERJET PRO®, HIRONIC is demonstrating strong potential in multiple application areas, including skin elasticity improvement, hydration, and drug delivery.During this review, HIRONIC received final conformity judgment from the Korea Testing & Research Institute (KTR) for SYNERJET PRO® as a combination medical device consisting of a jet injector and a low-frequency stimulator.Obtaining domestic approval for SYNERJET PRO® carries significant business value for HIRONIC. As SYNERJET, which had previously been supplied only for export, can now be officially used by domestic dermatology clinics, plastic surgery clinics, and medical aesthetic institutions, HIRONIC has secured a foundation for domestic sales growth. In addition, based on MFDS approval, which is highly trusted internationally, the company is expected to further strengthen its negotiating power with overseas buyers and partners.Furthermore, by securing domestic medical device status, HIRONIC will be able to formalize clinical cooperation with Korean medical specialists and build an official KOL (Key Opinion Leader) network. This approval is also expected to serve as an important precedent for future approval applications for next-generation needle-free injector lineups, including SYNERJET PRO®.HIRONIC plans to immediately proceed with the certification application to the National Institute of Medical Device Safety Information (NIDS), with the goal of receiving the final approval certificate within April 2026. After receiving the certificate, the company plans to accelerate individual certifications for major global markets, including the United States, and further establish its positioning as a premium needle-free injector brand. Reporter: Wonji Leenews21g@etnews.comOriginal Article: https://www.etnews.com/20260422000210
2026-05-18
|
|
|
HIRONIC participated in the American Society for Laser Medicine and Surgery (ASLMS), one of the world’s leading laser medicine conferences, where it showcased its key devices as part of its efforts to expand into the North American market.Celebrating its 45th edition this year, ASLMS is a representative conference in the field of laser-based medical devices. The event was held from May 7 to 9 at the Savannah Convention Center in Georgia, USA. With the participation of numerous global medical professionals and industry stakeholders, ASLMS served as a major platform for sharing the latest technological trends and clinical application cases.At the conference, HIRONIC introduced its core technologies and product competitiveness, focusing on expanding its presence in the global market. In particular, the company showcased the application methods and differentiated technological structures of its major export models, including MIGLOU™, which applies FIM™ (Focused Intensive Microwave) technology; SYNERJET PRO™, a non-invasive medical device designed to deliver active ingredients using Needle-free Microjetting technology; and NEW DOUBLO 2.0™, a comprehensive lifting platform that combines HIFU and RF technologies.In addition, HIRONIC conducted device demonstrations and consultations at its on-site booth, expanding contact points with medical professionals and buyers from various countries. Through these activities, the company strengthened its brand awareness in the North American market and explored practical opportunities for future business cooperation.A HIRONIC official stated, “ASLMS is a key conference where global medical professionals and industry stakeholders gather in one place, making it an important opportunity for us to directly present our technological capabilities and product competitiveness.” The official added, “Through our participation in this event, we have further accelerated our entry into the North American market in line with the global growth of K-beauty, and we will continue to expand our presence in overseas markets.”
2026-05-18
|
|
|
Hironic Co., Ltd. (CEO Lee Jin-woo) announced that it hosted a 'VVIP Partners Meeting' on the 20th at Park Hyatt Seoul, inviting global partner companies and Key Opinion Leaders (KOLs).This event was organized as a platform for communication where partners and medical professionals from various countries gathered to share clinical applications of Hironic's major medical devices, thereby enhancing technological competitiveness and brand reliability. In-depth discussions on product-specific features and actual clinical cases took place on-site.In particular, Hironic presented product details and clinical cases focusing on its core export devices: 'New Doublo 2.0', 'SYNERJET PRO™', and 'MIGLOU™'.It was emphasized that 'New Doublo 2.0', known domestically as 'V-RO LIFTING', combines Micro-Focused Ultrasound (MFU) and Radio Frequency (RF) to enable various customized treatments tailored to individual skin conditions.'SYNERJET PRO™', the export model of the KC-certified domestic 'SYNERJET', is an advanced medical aesthetic device that combines micro-jetting, electroporation, and plasma technologies to uniformly deliver active ingredients deep into the dermal layer.'MIGLOU™' garnered particularly intense interest during this meeting. Introduced domestically as 'MIGLOW', this device is designed to effectively deliver energy to targeted areas while minimizing the burden on the skin's surface by applying 2.45 GHz-based Ultra High Frequency (UHF) energy technology and a cooling system. The presentation also highlighted its versatility across various areas, including the face and body, and its ability to provide customized care through multiple handpieces.Active Q&A sessions regarding the technical characteristics, implementation feasibility, and application scope of 'MIGLOU™' took place on-site. Expectations were high for it as a next-generation aesthetic medical device due to its superior energy utilization efficiency compared to conventional RF equipment.A representative from Hironic stated, "Through this meeting, we have reinforced our collaborative relationships with global partners, and we will continue to strive for sustained improvement in product competitiveness and the expansion of our global network."
2026-04-20
|
|
|
Hironic Co., Ltd. announced that it has successfully concluded its participation in ‘KIMES 2026’ (Korea International Medical & Hospital Equipment Show), the largest medical device exhibition in Korea.KIMES is Korea’s premier exhibition that offers a comprehensive look at the latest technologies and trends in the medical industry. This year’s event once again garnered significant attention from industry professionals by showcasing a diverse array of medical devices and healthcare solutions.At the exhibition, Hironic showcased its flagship aesthetic medical devices, including ‘MIGLOU,’ ‘V-RO LIFTING,’ and ‘SYNERJET,’ actively engaging in product demonstrations and consultations with domestic and international medical professionals and buyers. Visitors to the booth observed live device demonstrations, leading to specific inquiries regarding the features and practical applications of the products.The new product, ‘MIGLOU,’ drew particular attention. Designed with 2.45 GHz-based UHF (Ultra-High Frequency) energy technology and an integrated cooling system, it is engineered to effectively deliver energy to targeted areas while minimizing strain on the skin's surface. It captured visitors' interest with its versatility, offering a variety of handpieces that allow for comprehensive treatments across both the face and the entire body.Additionally, ‘SYNERJET,’ a skin booster delivery device utilizing a microjet system, was highlighted for its ability to evenly distribute active ingredients while minimizing physical irritation.‘V-RO LIFTING,’ a device combining High-Intensity Focused Ultrasound (HIFU) and Radio Frequency (RF), was also featured. By simultaneously utilizing two types of energy from a single device, it enables a wide range of customized treatments tailored to individual skin conditions.An official from Hironic stated, "At KIMES 2026, we successfully showcased the technological prowess and practical applications of our core products to medical professionals and buyers from home and abroad." They added, "Having witnessed the enthusiastic response from our booth visitors, we will continuously strive to expand our presence in the global market and strengthen the competitiveness of our products."
2026-04-20
|